Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicentre randomised clinical trial.

Kucserik LP, Márta K, Vincze Á, Lázár G, Czakó L, Szentkereszty Z, Papp M, Palatka K, Izbéki F, Altorjay Á, Török I, Barbu S, Tantau M, Vereczkei A, Bogár L, Dénes M, Németh I, Szentesi A, Zádori N, Antal J, Lerch MM, Neoptolemos J, Sahin-Tóth M, Petersen OH, Kelemen D, Hegyi P.

BMJ Open. 2019 Jul 9;9(7):e025551. doi: 10.1136/bmjopen-2018-025551.

2.

Patient and general population values for luminal and perianal fistulising Crohn's disease health states.

Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL.

Eur J Health Econ. 2019 Jun;20(Suppl 1):91-100. doi: 10.1007/s10198-019-01065-y. Epub 2019 May 17.

3.

[Open transgastric necrosectomy for extended walled-off pancreas necrosis].

Balog K, Csiszkó A, Krasnyánszky N, Farkas M, Berhés M, László I, Palatka K, Damjanovich L, Sápy P, Szentkereszty Z.

Magy Seb. 2019 Mar;72(1):8-12. doi: 10.1556/1046.72.2019.1.2. Hungarian.

PMID:
30869532
4.

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.

Bálint A, Rutka M, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Szepes Z, Nagy F, Palatka K, Lovas S, Végh Z, Kürti Z, Csontos Á, Miheller P, Nyári T, Bor R, Milassin Á, Fábián A, Szántó K, Lakatos PL, Molnár T, Farkas K.

Expert Opin Biol Ther. 2018 Nov;18(11):1181-1187. doi: 10.1080/14712598.2018.1530758. Epub 2018 Oct 9.

PMID:
30277084
5.

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K.

Qual Life Res. 2019 Jan;28(1):141-152. doi: 10.1007/s11136-018-2003-4. Epub 2018 Sep 17.

PMID:
30225788
6.

The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study.

Palatka K, Kacska S, Lovas S, Garai I, Varga J, Galuska L.

Scand J Gastroenterol. 2018 Jan;53(1):24-30. doi: 10.1080/00365521.2017.1390600. Epub 2017 Oct 18.

PMID:
29043862
7.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.

Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL.

Inflamm Bowel Dis. 2017 Nov;23(11):1908-1915. doi: 10.1097/MIB.0000000000001237.

PMID:
28922253
8.

[Significance of the monitoring and screening for hereditary nonpolyposis colorectal carcinoma syndrome patients by presenting a case of a family tree].

Kóder G, Olasz J, Tóth L, Urbancsek H, András C, Bubán T, Palatka K, Damjanovich L, Tanyi M.

Orv Hetil. 2017 Jul;158(30):1182-1187. doi: 10.1556/650.2017.30803. Hungarian.

PMID:
28737456
9.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.

Bálint A, Rutka M, Végh Z, Kürti Z, Gecse KB, Banai J, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Patai Á, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Bor R, Milassin Á, Fábián A, Nagy F, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Lakatos PL, Molnár T, Farkas K.

Expert Opin Drug Saf. 2017 Aug;16(8):885-890. doi: 10.1080/14740338.2017.1323330. Epub 2017 May 26.

PMID:
28504555
10.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL.

J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203.

PMID:
27838610
11.

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T.

J Crohns Colitis. 2016 Nov;10(11):1273-1278. Epub 2016 Apr 21.

PMID:
27106537
12.

[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].

Rutka M, Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Molnár T.

Orv Hetil. 2016 May 1;157(18):706-11. doi: 10.1556/650.2016.30429. Hungarian.

PMID:
27106726
13.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL.

J Crohns Colitis. 2016 Feb;10(2):133-40. doi: 10.1093/ecco-jcc/jjv220. Epub 2015 Dec 10.

PMID:
26661272
14.

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.

Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Rutka M, Molnár T.

J Crohns Colitis. 2016 Jan;10(1):26-30. doi: 10.1093/ecco-jcc/jjv169. Epub 2015 Sep 20.

PMID:
26392413
15.

Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF-α treatment responders in inflammatory diseases.

Váradi C, Holló Z, Póliska S, Nagy L, Szekanecz Z, Váncsa A, Palatka K, Guttman A.

Electrophoresis. 2015 Jun;36(11-12):1330-5. doi: 10.1002/elps.201400575. Epub 2015 Apr 15.

PMID:
25639738
16.

Primary angiosarcoma of the pancreas mimicking severe acute pancreatitis--case report.

Csiszkó A, László I, Palatka K, Szabó KG, Kanyári Z, Bidiga L, Csonka T, Damjanovich L, Szentkereszty Z.

Pancreatology. 2015 Jan-Feb;15(1):84-7. doi: 10.1016/j.pan.2014.11.008. Epub 2014 Dec 6.

PMID:
25541144
17.

MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations.

Tanyi M, Olasz J, Tanyi JL, Tóth L, Antal-Szalmás P, Ress Z, Bubán T, Palatka K, András C, Urbancsek H, Garami Z, Csuka O, Damjanovich L.

Eur J Surg Oncol. 2014 Nov;40(11):1445-52. doi: 10.1016/j.ejso.2014.07.032. Epub 2014 Jul 24.

PMID:
25107687
18.

Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.

Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T, Molnár T.

Scand J Gastroenterol. 2013 Dec;48(12):1394-8. doi: 10.3109/00365521.2013.845906. Epub 2013 Oct 16.

PMID:
24131338
19.

Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.

Mesko B, Poliska S, Váncsa A, Szekanecz Z, Palatka K, Hollo Z, Horvath A, Steiner L, Zahuczky G, Podani J, Nagy AL.

Genome Med. 2013 Jun 28;5(6):59. doi: 10.1186/gm463. eCollection 2013.

20.

Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.

Kiss LS, Lovasz BD, Golovics PA, Vegh Z, Farkas K, Molnar T, Palatka K, Papp M, Mohas A, Szilagyi BK, Fekete SA, Mandel M, Lakatos PL.

J Gastrointestin Liver Dis. 2013 Jun;22(2):135-40.

21.

[Severe anemia caused by haemorrhoids: the casae of a young man with toxic cirrhosis].

Kovács E, Palatka K, Németh A, Pásztor É, Pfliegler G.

Orv Hetil. 2013 Mar 10;154(10):382-6. doi: 10.1556/OH.2013.29561. Hungarian.

PMID:
23461979
22.

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy.

Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M, Palatka K, Nyári T, Bálint A, Lőrinczy K, Wittmann T.

Aliment Pharmacol Ther. 2013 Jan;37(2):225-33. doi: 10.1111/apt.12160. Epub 2012 Nov 26.

23.

Catheter-directed thrombolysis in inflammatory bowel diseases: report of a case.

Ilonczai P, Tóth J, Tóth L, Altorjay I, Boda Z, Palatka K.

World J Gastroenterol. 2012 Sep 14;18(34):4791-3.

24.

Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?

Horváth G, Farkas K, Hollósi R, Nagy F, Szepes Z, Papp M, Palatka K, Miheller P, Lakatos L, Szamosi T, Nyári T, Wittmann T, Molnár T.

Scand J Gastroenterol. 2012 Nov;47(11):1298-303. doi: 10.3109/00365521.2012.703233. Epub 2012 Aug 31.

PMID:
22935014
25.

[Hungarian data on inflammatory bowel diseases: analytical data on ulcerative colistis].

Miheller P, Nagy F, Palatka K, Altorjay I, Horváth G, Lőrinczy K, Újszászy L, Virányi Z, Szepes A, Molnár T, Farkas K, Szepes Z, Nyári T, Wittmann T, Tulassay Z.

Orv Hetil. 2012 May 6;153(18):702-12. doi: 10.1556/OH.2012.29361. Hungarian.

PMID:
22547465
26.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group.

Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24.

27.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL.

Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200. Hungarian.

PMID:
21865144
28.

Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort.

Poliska S, Penyige A, Lakatos PL; Hungarian IBD Study Group, Papp M, Palatka K, Lakatos L, Molnar T, Nagy L.

Inflamm Bowel Dis. 2012 Mar;18(3):472-9. doi: 10.1002/ibd.21798. Epub 2011 Jun 24.

PMID:
21710534
29.

Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.

Altorjay I, Veréb Z, Serfozo Z, Bacskai I, Bátori R, Erdodi F, Udvardy M, Sipka S, Lányi Á, Rajnavölgyi É, Palatka K.

Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):323-35.

PMID:
21658307
30.

Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis.

Vitalis Z, Altorjay I, Tornai I, Palatka K, Kacska S, Palyu E, Tornai D, Udvardy M, Harsfalvi J, Dinya T, Veres G, Lakatos PL, Papp M.

Hum Immunol. 2011 Apr;72(4):348-54. doi: 10.1016/j.humimm.2011.01.008. Epub 2011 Jan 21.

PMID:
21262313
31.

Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.

Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, Kristof T, Nagy F, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovacs A, Racz I, Lakatos L.

J Crohns Colitis. 2010 Sep;4(3):283-90. doi: 10.1016/j.crohns.2009.11.011.

PMID:
21122517
32.

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.

Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M.

Inflamm Bowel Dis. 2011 Mar;17(3):767-77. doi: 10.1002/ibd.21402. Epub 2010 Sep 23.

PMID:
20865702
33.

Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis.

Altorjay I, Vitalis Z, Tornai I, Palatka K, Kacska S, Farkas G, Udvardy M, Harsfalvi J, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Csak T, Osztovits J, Szalay F, Csepregi A, Lakatos PL, Papp M.

J Hepatol. 2010 Sep;53(3):484-91. doi: 10.1016/j.jhep.2010.03.028. Epub 2010 Jun 2.

PMID:
20605050
34.

Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets.

Mesko B, Poliska S, Szegedi A, Szekanecz Z, Palatka K, Papp M, Nagy L.

BMC Med Genomics. 2010 May 5;3:15. doi: 10.1186/1755-8794-3-15.

35.

[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].

Lakatos L, Czeglédi Z, Dávid G, Kispál Z, Kiss LS, Palatka K, Kristóf T, Molnár T, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovács A, Rácz I, Lakatos PL.

Orv Hetil. 2010 Feb 14;151(7):250-8. doi: 10.1556/OH.2010.28805. Hungarian.

PMID:
20133244
36.

Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort.

Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, Farkas K, Nagy F, Veres G, Lakatos L, Kovacs A, Dinya T, Kocsis AK, Papp J; Hungarian IBD Study Group, Altorjay I.

Hum Immunol. 2010 Apr;71(4):407-13. doi: 10.1016/j.humimm.2010.01.012. Epub 2010 Jan 26.

PMID:
20079790
37.

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.

Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabó A, Gelley A, Lakatos L, Barta Z, Balázs C, Rácz I, Zeher M, Döbrönte Z, Altorjay I, Hunyady B, Simon L, Papp J, Banai J, Nagy F, Lonovics J, Ujszászy L, Muzes G, Herszényi L, Tulassay Z.

BMC Gastroenterol. 2009 Sep 10;9:66. doi: 10.1186/1471-230X-9-66.

38.

Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, Palatka K, Veres G, Udvardy M, Lakatos PL.

Clin Vaccine Immunol. 2009 Apr;16(4):464-70. doi: 10.1128/CVI.00002-09. Epub 2009 Feb 4.

39.

Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.

Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M; Hungarian IBD Study Group.

Inflamm Bowel Dis. 2009 Mar;15(3):365-74. doi: 10.1002/ibd.20778.

PMID:
18972554
40.

[Laboratory diagnostics of pleural effusion].

Jakubec P, Palatka K, Jakubcová T, Kolek V.

Vnitr Lek. 2008 Mar;54(3):265-72. Review. Czech.

PMID:
18522295
41.

Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?

Lakatos PL, Altorjay I, Mándi Y, Lakatos L, Tumpek J, Kovacs A, Molnar T, Tulassay Z, Miheller P, Palatka K, Szamosi T, Fischer S, Papp J; Hungarian IBD Study Group, Papp M.

Tissue Antigens. 2008 Jun;71(6):552-9. doi: 10.1111/j.1399-0039.2008.01049.x. Epub 2008 Apr 7.

PMID:
18397186
42.

New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.

Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; Hungarian IBD Study Group, Lakatos PL.

Am J Gastroenterol. 2008 Mar;103(3):665-81. Epub 2007 Nov 28.

PMID:
18047543
43.

NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease.

Molnar T, Hofner P, Nagy F, Lakatos PL, Fischer S, Lakatos L, Kovacs A, Altorjay I, Papp M, Palatka K, Demeter P, Tulassay Z, Nyari T, Miheller P, Papp J, Mandi Y, Lonovics J; Hungarian IBD Study Group.

Dig Liver Dis. 2007 Dec;39(12):1064-70. Epub 2007 Oct 26.

PMID:
17964870
44.

Thyroid hormones affect the level and activity of nitric oxide synthase in rat cerebral cortex during postnatal development.

Serfozo Z, Kiss PB, Kukor Z, Lontay B, Palatka K, Varga V, Erdodi F, Elekes K.

Neurochem Res. 2008 Mar;33(3):569-78. Epub 2007 Oct 17.

PMID:
17940896
45.

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J; Hungarian IBD Study Group, Lakatos PL.

Inflamm Bowel Dis. 2007 Aug;13(8):984-92.

PMID:
17417801
46.

Haptoglobin polymorphisms are associated with Crohn's disease, disease behavior, and extraintestinal manifestations in Hungarian patients.

Papp M, Lakatos PL; Hungarian IBD Study Group, Palatka K, Foldi I, Udvardy M, Harsfalvi J, Tornai I, Vitalis Z, Dinya T, Kovacs A, Molnar T, Demeter P, Papp J, Lakatos L, Altorjay I.

Dig Dis Sci. 2007 May;52(5):1279-84. Epub 2007 Mar 15.

PMID:
17357835
47.

[Haptoglobin polymorphism in patients with inflammatory bowel diseases].

Papp M, Lakatos PL; Hungarian IBD Study Group, Palatka K, Földi I, Udvardy M, Hársfalvi J, Tornai I, Vitális Z, Dinya T, Kovács A, Molnár T, Demeter P, Papp J, Lakatos L, Altorjay I.

Orv Hetil. 2006 Sep 10;147(36):1745-50. Hungarian.

PMID:
17087019
48.
49.

DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease.

Lakatos PL, Fischer S, Claes K, Kovacs A, Molnar T, Altorjay I, Demeter P, Tulassay Z, Palatka K, Papp M, Rutgeerts P, Szalay F, Papp J, Vermeire S, Lakatos L; Hungarian IBD Study Group.

Inflamm Bowel Dis. 2006 May;12(5):362-8.

PMID:
16670524
50.

Effect of IBD sera on expression of inducible and endothelial nitric oxide synthase in human umbilical vein endothelial cells.

Palatka K, Serfozo Z, Veréb Z, Bátori R, Lontay B, Hargitay Z, Nemes Z, Udvardy M, Erdodi F, Altorjay I.

World J Gastroenterol. 2006 Mar 21;12(11):1730-8.

Supplemental Content

Loading ...
Support Center